Terminal lucidity

Last updated

Terminal lucidity (also known as rallying, terminal rally, the rally, end-of-life-experience, energy surge, the surge, or pre-mortem surge) [1] is an unexpected return of consciousness, mental clarity or memory shortly before death in individuals with severe psychiatric or neurological disorders. [2] [3] It has been reported by physicians since the 19th century. Terminal lucidity is a narrower term than the phenomenon paradoxical lucidity where return of mental clarity can occur anytime (not just before death). [4] [5] However, as of 2024, terminal lucidity is not considered a medical term and there is no official consensus on the identifying characteristics. [6]

Contents

Terminal lucidity is a poorly understood phenomenon in the context of medical and psychological research, and there is no consensus on what the underlying mechanisms are. Its existence challenges the irreversibility paradigm of chronic degenerative dementias.

Studying terminal lucidity presents ethical challenges due to the need for informed consent. Care providers also have ethical challenges of whether to provide deep sedation, which might limit terminal lucidity, and how to respond to requests for a change in care plans from family members.

History

Several case reports in the 19th century described the unusual condition of an improvement and recovery of the mental state in people days or weeks before death. In 1887, William Munk called the phenomenon "lightening up before death". [7]

According to historical reviews headed by the biologist Michael Nahm, the phenomenon have been noted in individuals with diseases which cause progressive cognitive impairment, such as Alzheimer's disease, but also schizophrenia, tumors, strokes, meningitis, and Parkinson's disease. [8] [9] [10] This makes terminal lucidity a phenomenon that is difficult to classify. Researchers are unclear if the phenomenon occurs in all people regardless of their medical history. [11] [12] In 2018, a group of researchers at Dongguk University Ilsan Hospital published a study involving the observation of people weeks prior to death. Out of 151 deaths, six people experienced terminal lucidity. These six had different admission causes, and upon admission three of them were alert and aware and the other three were drowsy. The most common causes of death among these people were different infectious diseases or cancer complications. [13] A survey of 45 Canadian palliative care volunteers reported that 33% of them personally witnessed at least one case of terminal lucidity within the past year. [14]

According to Nahm, it may be present even in cases of people with previous mental disability. [15] Nahm defines two subtypes: one that comes gradually (a week before death), and another that comes rapidly (hours before death), with the former occurring more often than the latter. There are many cases reported in literature, although the phrase terminal lucidity was coined in 2009. [16] Interest in this condition, which dwindled during the 20th century, has been reignited by further studies. [17]

Characteristics

Terminal lucidity is commonly characterized by a potential reduction in the severity of the individual's physical symptoms. For example, those who were previously non-verbal or may have limited communication abilities may regain their ability to speak. Additionally, there may be an increase in cheerfulness or renewed interest in eating and drinking.[ citation needed ] People with memory problems such as Alzheimer's disease or dementia may experience sudden recollection and recognition of people they had previously lost the ability to identify.[ citation needed ]

During terminal lucidity, cognitive and memory abilities function differently than those of unaffected individuals. [10]

Similarity to paradoxical lucidity

Research in 2020 screened for "paradoxical lucidity", a general term for unexpected remissions in dementias, independent of whether the person died shortly thereafter. The research found that in only 6% of the paradoxical lucidity cases did the person live longer than a week, and stated that it is a "primarily death-related phenomenon". [8] A 2021 systematic review attempted to define the parameters of paradoxical lucidity and recommended three criteria: the person must present with a neurological condition; the condition must be considered irreversible; the condition hinders normal verbal/behavioral capabilities. [4]

These stipulations are not static and are subject to change. For instance, the second criterion states the condition must be considered irreversible. But as new research emerges and more insight is gained on previously poorly understood mechanisms involving the brain, it may be discovered that what was initially assumed to be permanent is actually reversible.

Paradoxical lucidity is considered a challenge to the irreversibility paradigm of chronic degenerative dementias. [18] The similarities between paradoxical and terminal lucidity may suggest a shared common mechanism. Having a thorough understanding of both types of phenomenon can facilitate researchers in advancing the scope of their study.  

Possible mechanisms

All proposed mechanisms should be considered as anecdotal evidence and hypothetical because there are no neuroscientific studies of terminal lucidity. However, near-death experiences, a related concept to terminal lucidity, can provide insight into possible mechanisms.

Near-death experiences have been reported worldwide, independent of culture, by people who unexpectedly recovered from life-threatening injury or by individuals who escaped a potentially fatal situation. People have described their near-death experience as an "out-of-body experience", "sense of unity with nature", "apparent memory of a previous life", etc. [19] [20] Near-death experiences are similar to terminal lucidity because they both occur just before death.

There is little research on the mechanism of near-death experiences because it is hard to determine who will experience them. Case reports have found that there is a sudden increase in brain electrical activity that is normally associated with consciousness in people who are dying due to critical illness. [21] [22] [23] Even though this electrical abnormality could just be cell membrane losing activity because of lack of oxygen, it is possible that the surge of neurophysiological activity before death is related to terminal lucidity. [24]

Timeline

A study reviewing existing case reports, mostly from physicians during the 19th century, found that 84% of people who have moments of mental clarity before dying usually die within a week, and 43% of them die within 24 hours. [25] A more recent study in Europe and the United States that surveyed healthcare providers of people who have severe memory problems discovered that these moments of mental clarity lasted up to 24 hours in 87% of cases, and 79% of those cases involved people who could communicate clearly and coherently. About 66% of patients died within two days of experiencing mental clarity. [8]

Early research

The earliest attempt at explanation was issued by Benjamin Rush in 1812, which hypothesized that a reawakening could be due to a nervous excitation caused by pain or fever, or because of dead blood vessels, released by a leakage of water in the brain chambers. [26]

In 1826, Karl Friedrich Burdach, a physiologist and anatomist, focused on the anatomy of the brains of people who died and experienced this phenomenon. He noted changes in their brains, for example, there was blood outflow within the brain, presence of an unusual fluid filling the brain, increase in the size of the brain or softening in some parts of the brain. [27]

In 1839, Johannes Friedreich, a physician, reviewed multiple case reports of people who experienced terminal lucidity. He proposed that the factors causing impairments and brain dysfunctions may be reversed shortly before death, because some studies showed that people who have water in their brains (hydrocephalus) will have less water before they die. [27] He suggested that this could be induced by fever, but none of the terminal lucidity cases included high fever or deteriorated brain tissues.

Current research

In 2009, Macleod reached conclusions based on his own observations, rather than witness statements which the majority of other case studies used. Out of 100 deaths that happened in a hospice, 6 cases experienced terminal lucidity which lasted 12 hours and the people died 48 hours later. Benzodiazepines (medications to decrease arousal) and anti-emetics (medications to ease nausea and vomiting) were used, but their doses did not exceed the recommended maximum, although a high dose of an opioid was used in one case. Macleod was not able to find any predictors or causes of terminal lucidity, but he suggested that terminal lucidity was more common in the past because in modern pharmacology there are guidelines and recommendations for medication usage. For example, doctors in the past did not have a dosage limit for opioids, and did not have the medications to ease nausea and vomiting. [17] [28]

In 2018, the US National Institute on Aging (NIA) announced two funding opportunities in order to encourage scientists to advance nascent science of lucidity. [29] Of these funded studies, a lab at New York University was awarded a five-year grant in 2020 for their proposal to measure the actual brain activity, record audio and video, and have caregivers keep diaries, making it the first in depth study focusing on lucidity in dementia patients. [30]

In 2021, a non-tested hypothesis of neuromodulation was proposed, whereby near-death discharges of neurotransmitters and corticotropin-releasing peptides act upon preserved circuits of the medial prefrontal cortex and hippocampus, promoting memory retrieval and mental clarity. This study also proposed a relationship between lucid dreaming and terminal lucidity, suggesting further research should be conducted to explore the similarities of brain signals between the two. [31]

Ongoing research

A study by NYU Langone Health in collaboration with the NIA which began in 2022 and is set to end in 2025 "aims to establish methods for measuring episodes of lucidity" in people with severe end-stage dementia. [32]

The Penn Program on Precision Medicine for the Brain (P3MB) have several current projects in the works in partnership with various organizations such as the Alzheimer's Association, the CDC, and the NIA. [33] Undertaking a multidisciplinary approach, P3MB conducts and participates in various research involving neurological diseases with the aim to potentially translate new discoveries into clinical practice. Their discoveries have the potential to influence the current understanding of terminal lucidity.

Ethical considerations

In his 2009 study, Macleod discussed how modern medical practices, such as the use of sedative medications, may contribute to the rarity of terminal lucidity. Deep sedation, which is often used to alleviate intractable symptoms, could deprive patients of the opportunity to experience moments of clarity and connection with loved ones before dying. [28]

Understanding the mechanism behind terminal lucidity has ethical implications for how researchers design studies. Study participants with severe neurological disorders such as schizophrenia or dementia may not have the capacity to provide informed consent. [34] Another ethical issue is whether study participation is voluntary. Care-givers or administrators at nursing homes and long-term care facilities may exert undue influence on individuals living there. One report stated "voluntarism of vulnerable subjects is usually compromised". [34] Another report recommended having policy discussions and protocols in place that can address and minimize the potential for harm to the individual. [35] [36] Ethical dilemmas may arise in cases of individuals with advanced cognitive impairment who experience terminal lucidity, because healthcare providers must balance respecting previously expressed wishes with any newfound information presented during the lucid episode. One report recommended early conversations between end-of-life patients and healthcare providers so that medical decisions can be made that are in line with each patient's values and preferences, even in the presence of fluctuating cognitive states. [37]

Terminal lucidity may have a significant influence on families. Some family members may believe that their loved ones are improving, only to experience their death soon after. After an episode of consciousness, family members may request the clinicians to modify the care plan hoping for a recurrence of such moments. Clinicians are also affected as they try to help and comfort the family members who are dealing with a phenomenon that is not well-understood. [37] Terminal lucidity may provide a positive experience for family members who see these moments of clarity as a way to resolve unfinished business, reach closure, or reaffirm spiritual beliefs. As a result, several reports recommend providing guidelines for clinical practice. [38]

Related Research Articles

<span class="mw-page-title-main">Dementia</span> Long-term brain disorders causing impaired memory, thinking and behavior

Dementia is a syndrome associated with many neurodegenerative diseases, characterized by a general decline in cognitive abilities that affects a person's ability to perform everyday activities. This typically involves problems with memory, thinking, behavior, and motor control. Aside from memory impairment and a disruption in thought patterns, the most common symptoms of dementia include emotional problems, difficulties with language, and decreased motivation. The symptoms may be described as occurring in a continuum over several stages. Dementia ultimately has a significant effect on the individual, their caregivers, and their social relationships in general. A diagnosis of dementia requires the observation of a change from a person's usual mental functioning and a greater cognitive decline than might be caused by the normal aging process.

Delirium is a specific state of acute confusion attributable to the direct physiological consequence of a medical condition, effects of a psychoactive substance, or multiple causes, which usually develops over the course of hours to days. As a syndrome, delirium presents with disturbances in attention, awareness, and higher-order cognition. People with delirium may experience other neuropsychiatric disturbances including changes in psychomotor activity, disrupted sleep-wake cycle, emotional disturbances, disturbances of consciousness, or, altered state of consciousness, as well as perceptual disturbances, although these features are not required for diagnosis.

Palliative care is an interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex, and often terminal illnesses. Within the published literature, many definitions of palliative care exist. The World Health Organization (WHO) describes palliative care as "an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain, illnesses including other problems whether physical, psychosocial, and spiritual". In the past, palliative care was a disease specific approach, but today the WHO takes a broader patient-centered approach that suggests that the principles of palliative care should be applied as early as possible to any chronic and ultimately fatal illness. This shift was important because if a disease-oriented approach is followed, the needs and preferences of the patient are not fully met and aspects of care, such as pain, quality of life, and social support, as well as spiritual and emotional needs, fail to be addressed. Rather, a patient-centered model prioritizes relief of suffering and tailors care to increase the quality of life for terminally ill patients.

In medicine, specifically in end-of-life care, palliative sedation is the palliative practice of relieving distress in a terminally ill person in the last hours or days of a dying person's life, usually by means of a continuous intravenous or subcutaneous infusion of a sedative drug, or by means of a specialized catheter designed to provide comfortable and discreet administration of ongoing medications via the rectal route.

Terminal illness or end-stage disease is a disease that cannot be cured or adequately treated and is expected to result in the death of the patient. This term is more commonly used for progressive diseases such as cancer, dementia, advanced heart disease, and for HIV/AIDS, or long COVID in bad cases, rather than for injury. In popular use, it indicates a disease that will progress until death with near absolute certainty, regardless of treatment. A patient who has such an illness may be referred to as a terminal patient, terminally ill or simply as being terminal. There is no standardized life expectancy for a patient to be considered terminal, although it is generally months or less. Life expectancy for terminal patients is a rough estimate given by the physician based on previous data and does not always reflect true longevity. An illness which is lifelong but not fatal is a chronic condition.

Memory disorders are the result of damage to neuroanatomical structures that hinders the storage, retention and recollection of memories. Memory disorders can be progressive, including Alzheimer's disease, or they can be immediate including disorders resulting from head injury.

<span class="mw-page-title-main">Organic brain syndrome</span> Disorder of mental function whose cause is alleged to be known as physiological

Organic brain syndrome, also known as organic brain disease, organic brain damage, organic brain disorder (OBD), organic mental syndrome, or organic mental disorder, refers to any syndrome or disorder of mental function whose cause is alleged to be known as organic (physiologic) rather than purely of the mind. These names are older and nearly obsolete general terms from psychiatry, referring to many physical disorders that cause impaired mental function. They are meant to exclude psychiatric disorders. Originally, the term was created to distinguish physical causes of mental impairment from psychiatric disorders, but during the era when this distinction was drawn, not enough was known about brain science for this cause-based classification to be more than educated guesswork labeled with misplaced certainty, which is why it has been deemphasized in current medicine. While mental or behavioural abnormalities related to the dysfunction can be permanent, treating the disease early may prevent permanent damage in addition to fully restoring mental functions. An organic cause to brain dysfunction is suspected when there is no indication of a clearly defined psychiatric or "inorganic" cause, such as a mood disorder.

Lytico-bodig (also Lytigo-bodig) disease, Guam disease, or amyotrophic lateral sclerosis-parkinsonism-dementia (ALS-PDC) is a neurodegenerative disease of uncertain etiology endemic to the Chamorro people of the island of Guam in Micronesia. Lytigo and bodig are Chamorro language words for two different manifestations of the same condition. ALS-PDC, a term coined by Asao Hirano and colleagues in 1961, reflects its resemblance to amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease.

End-of-life care (EOLC) is health care provided in the time leading up to a person's death. End-of-life care can be provided in the hours, days, or months before a person dies and encompasses care and support for a person's mental and emotional needs, physical comfort, spiritual needs, and practical tasks.

Pseudodementia is a condition that leads to cognitive and functional impairment imitating dementia that is secondary to psychiatric disorders, especially depression. Pseudodementia can develop in a wide range of neuropsychiatric disease such as depression, schizophrenia and other psychosis, mania, dissociative disorders, and conversion disorders. The presentations of pseudodementia may mimic organic dementia, but are essentially reversible on treatment and doesn't lead to actual brain degeneration. However, it has been found that some of the cognitive symptoms associated with pseudodementia can persist as residual symptoms and even transform into true neurodegenerative dementia in some cases.

As populations age, caring for people with dementia has become more common. Elderly caregiving may consist of formal care and informal care. Formal care involves the services of community and medical partners, while informal care involves the support of family, friends, and local communities. In most mild-to-medium cases of dementia, the caregiver is a spouse or an adult child. Over a period of time, more professional care in the form of nursing and other supportive care may be required medically, whether at home or in a long-term care facility. There is evidence to show that case management can improve care for individuals with dementia and the experience of their caregivers. Furthermore, case management may reduce overall costs and institutional care in the medium term. Millions of people living in the United States take care of a friend or family member with Alzheimer’s disease or a related dementia.

<span class="mw-page-title-main">Posterior cortical atrophy</span> Medical condition

Posterior cortical atrophy (PCA), also called Benson's syndrome, is a rare form of dementia which is considered a visual variant or an atypical variant of Alzheimer's disease (AD). The disease causes atrophy of the posterior part of the cerebral cortex, resulting in the progressive disruption of complex visual processing. PCA was first described by D. Frank Benson in 1988.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to twelve years.

Sundowning, or sundown syndrome, is a neurological phenomenon associated with increased confusion and restlessness in people with delirium or some form of dementia. It is most commonly associated with Alzheimer's disease but is also found in those with other forms of dementia. The term sundowning was coined by nurse Lois K. Evans in 1987 due to the timing of the person's increased confusion beginning in the late afternoon and early evening. For people with sundown syndrome, a multitude of behavioral problems begin to occur and are associated with long-term adverse outcomes. Sundowning seems to occur more frequently during the middle stages of Alzheimer's disease and mixed dementia and seems to subside with the progression of the person's dementia. People are generally able to understand that this behavioral pattern is abnormal. Research shows that 20–45% of people with Alzheimer's will experience some variation of sundowning confusion. However, despite lack of an official diagnosis of sundown syndrome in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), there is currently a wide range of reported prevalence.

<span class="mw-page-title-main">Near-death experience</span> Personal experiences associated with death or impending death

A near-death experience (NDE) is a profound personal experience associated with death or impending death, which researchers describe as having similar characteristics. When positive, which the great majority are, such experiences may encompass a variety of sensations including detachment from the body, feelings of levitation, total serenity, security, warmth, joy, the experience of absolute dissolution, review of major life events, the presence of a light, and seeing dead relatives. When negative, such experiences may include sensations of anguish, distress, a void, devastation, and seeing hellish imagery.

Caregiver syndrome or caregiver stress is a condition that strongly manifests exhaustion, anger, rage, or guilt resulting from unrelieved caring for a chronically ill patient. This condition is not listed in the United States' Diagnostic and Statistical Manual of Mental Disorders, although the term is often used by many healthcare professionals in that country. The equivalent used in many other countries, the ICD-11, does include the condition.

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

Sam Parnia is a British associate professor of Medicine at the NYU Langone Medical Center where he is also director of research into cardiopulmonary resuscitation. In the United Kingdom, he is director of the Human Consciousness Project at the University of Southampton. Parnia is known for his work on near-death experiences and cardiopulmonary resuscitation.

<span class="mw-page-title-main">Deathbed phenomena</span> Range of phenomena reported by dying people

Deathbed phenomena refers to a range of experiences reported by people who are dying. There are many examples of deathbed phenomena in both non-fiction and fictional literature, which suggests that these occurrences have been noted by cultures around the world for centuries, although scientific study of them is relatively recent. In scientific literature such experiences have been referred to as death-related sensory experiences (DRSE). Dying patients have reported to staff working in hospices they have experienced comforting visions.

Although there are many physiological and psychological gender differences in humans, memory, in general, is fairly stable across the sexes. By studying the specific instances in which males and females demonstrate differences in memory, we are able to further understand the brain structures and functions associated with memory.

References

  1. ↑ Julião, Miguel; Wholihan, Dorothy J.; Calaveiras, Patrícia; Costa, Elisabeth; Sousa, Paulo Faria de (April 2023). "Energy surge: A deathbed phenomenon that matters". Palliative & Supportive Care. 21 (2): 371–375. doi: 10.1017/S1478951522001754 . ISSN   1478-9515. PMID   36700451. S2CID   256273070.
  2. ↑ Mendoza MA (October 10, 2018). "Why Some People Rally for One Last Goodbye Before Death". Psychology Today (blog). Retrieved 26 August 2019.
  3. ↑ Bursack CB. "When Loved Ones Rally Before Death". AgingCare. Archived from the original on 26 August 2019. Retrieved 26 August 2019.
  4. 1 2 Peterson A, Clapp J, Largent EA, Harkins K, Stites SD, Karlawish J (March 2022). "What is paradoxical lucidity? The answer begins with its definition". Alzheimer's & Dementia. 18 (3): 513–521. doi:10.1002/alz.12424. PMC   8807788 . PMID   34338400.
  5. ↑ Eldadah BA, Fazio EM, McLinden KA (August 2019). "Lucidity in dementia: A perspective from the NIA". Alzheimer's & Dementia. 15 (8): 1104–1106. doi: 10.1016/j.jalz.2019.06.3915 . PMID   31422799. S2CID   199577248.
  6. ↑ "Terminal lucidity and dementia: Definition and causes". www.medicalnewstoday.com. 2022-08-30. Archived from the original on 2023-08-04. Retrieved 2023-08-04.
  7. ↑ Clark D (November 2016). "Nineteenth-century doctors and care of the dying". Oxford Medicine Online. doi:10.1093/med/9780199674282.003.0001.
  8. 1 2 3 Batthyány A, Greyson B (2020-08-27). "Spontaneous remission of dementia before death: Results from a study on paradoxical lucidity". Psychology of Consciousness: Theory, Research, and Practice. 8: 1–8. doi:10.1037/cns0000259. ISSN   2326-5531. S2CID   225192667.
  9. ↑ Nahm M, Greyson B (December 2009). "Terminal lucidity in patients with chronic schizophrenia and dementia: a survey of the literature". The Journal of Nervous and Mental Disease. 197 (12): 942–944. doi:10.1097/NMD.0b013e3181c22583. PMID   20010032.
  10. 1 2 Nahm M, Greyson B, Kelly EW, Haraldsson E (July–August 2012). "Terminal lucidity: a review and a case collection". Archives of Gerontology and Geriatrics. 55 (1): 138–142. doi:10.1016/j.archger.2011.06.031. PMID   21764150.
  11. ↑ "Supplemental Material for Spontaneous Remission of Dementia Before Death: Results From a Study on Paradoxical Lucidity". Psychology of Consciousness: Theory, Research, and Practice. 2020-08-27. doi:10.1037/cns0000259.supp. ISSN   2326-5523. S2CID   243215930.
  12. ↑ Gilmore-Bykovskyi A, Griffin JM, Mueller KD, Parnia S, Kolanowski A (January 2023). "Toward harmonization of strategies for investigating lucidity in AD/ADRD: A preliminary research framework". Alzheimer's & Dementia. 19 (1): 343–352. doi:10.1002/alz.12709. PMC   9792622 . PMID   35757902.
  13. ↑ Lim CY, Park JY, Kim DY, Yoo KD, Kim HJ, Kim Y, Shin SJ (2018-12-04). "Terminal lucidity in the teaching hospital setting". Death Studies. 44 (5): 285–291. doi:10.1080/07481187.2018.1541943. PMID   30513269. S2CID   54599516.
  14. ↑ Claxton-Oldfield S, Dunnett A (2016-09-21). "Hospice Palliative Care Volunteers' Experiences With Unusual End-of-Life Phenomena". OMEGA - Journal of Death and Dying. 77 (1): 3–14. doi:10.1177/0030222816666541. ISSN   0030-2228. S2CID   79231764. Archived from the original on 2023-08-03. Retrieved 2023-08-03.
  15. ↑ Nahm M, Greyson B (2014). "The death of Anna Katharina Ehmer: a case study in terminal lucidity". Omega. 68 (1): 77–87. doi:10.2190/OM.68.1.e. PMID   24547666. S2CID   1265185.
  16. ↑ Bering J (2017). "One Last Goodbye: The Strange Case of Terminal Lucidity". Scientific American Blog Network. Archived from the original on 2021-03-27. Retrieved 2021-03-27.
  17. 1 2 Chiriboga-Oleszczak BA (2017-03-28). "Terminal lucidity". Current Problems of Psychiatry. 18 (1): 34–46. doi: 10.1515/cpp-2017-0003 . ISSN   2353-8627.
  18. ↑ Mashour GA, Frank L, Batthyany A, Kolanowski AM, Nahm M, Schulman-Green D, et al. (August 2019). "Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias". Alzheimer's & Dementia. 15 (8): 1107–1114. doi: 10.1016/j.jalz.2019.04.002 . hdl: 2027.42/153062 . PMID   31229433.
  19. ↑ Greyson B, Stevenson I (October 1980). "The phenomenology of near-death experiences". The American Journal of Psychiatry. 137 (10): 1193–1196. doi:10.1176/ajp.137.10.1193. PMID   7416264.
  20. ↑ van Lommel P (October 2011). "Near-death experiences: the experience of the self as real and not as an illusion". Annals of the New York Academy of Sciences. 1234 (1): 19–28. Bibcode:2011NYASA1234...19V. doi:10.1111/j.1749-6632.2011.06080.x. PMID   21988246. S2CID   23740782.
  21. ↑ Chawla LS, Akst S, Junker C, Jacobs B, Seneff MG (December 2009). "Surges of electroencephalogram activity at the time of death: a case series". Journal of Palliative Medicine. 12 (12): 1095–1100. doi:10.1089/jpm.2009.0159. PMID   19803731.
  22. ↑ Auyong DB, Klein SM, Gan TJ, Roche AM, Olson D, Habib AS (May 2010). "Processed electroencephalogram during donation after cardiac death". Anesthesia and Analgesia. 110 (5): 1428–1432. doi: 10.1213/ANE.0b013e3181d27067 . PMID   20237048. S2CID   45699061.
  23. ↑ Chawla LS, Terek M, Junker C, Akst S, Yoon B, Brasha-Mitchell E, Seneff MG (July 2017). "Characterization of end-of-life electroencephalographic surges in critically ill patients". Death Studies. 41 (6): 385–392. doi:10.1080/07481187.2017.1287138. PMID   28145850. S2CID   34027870.
  24. ↑ Mashour GA, Frank L, Batthyany A, Kolanowski AM, Nahm M, Schulman-Green D, et al. (August 2019). "Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias". Alzheimer's & Dementia. 15 (8): 1107–1114. doi: 10.1016/j.jalz.2019.04.002 . hdl: 2027.42/153062 . PMID   31229433. S2CID   195063786.
  25. ↑ Ijaopo EO, Zaw KM, Ijaopo RO, Khawand-Azoulai M (2023-06-26). "A Review of Clinical Signs and Symptoms of Imminent End-of-Life in Individuals With Advanced Illness". Gerontology & Geriatric Medicine. 9: 23337214231183243. doi:10.1177/23337214231183243. PMC   10327414 . PMID   37426771.
  26. ↑ Rush B (1830). Medical inquiries and observations upon the diseases of the mind. Medicine in the Americas, 1610-1920 (4th ed.). Philadelphia: Grigg. Archived from the original on 2023-08-02. Retrieved 2023-08-02– via Digital Collections - National Library of Medicine.
  27. 1 2 Nahm, Michael (2009). "Terminal Lucidity in People with Mental Illness and Other Mental Disability: An Overview and Implications for Possible Explanatory Models". Journal of Near-Death Studies. 28 (2): 87–106. doi:10.17514/JNDS-2009-28-2-p87-106.. ISSN   0891-4494. Archived from the original on 2023-07-31. Retrieved 2023-07-31.{{cite journal}}: CS1 maint: ignored DOI errors (link)
  28. 1 2 Macleod AD (December 2009). "Lightening up before death". Palliative & Supportive Care. 7 (4): 513–516. doi:10.1017/S1478951509990526. PMID   19939314. S2CID   27769470.
  29. ↑ Eldadah, Basil A.; Fazio, Elena M.; McLinden, Kristina A. (2019-08-01). "Lucidity in dementia: A perspective from the NIA". Alzheimer's & Dementia. 15 (8): 1104–1106. doi: 10.1016/j.jalz.2019.06.3915 . PMID   31422799. S2CID   199577248.
  30. ↑ "New Studies Explore End-of-Life Cognitive Thought & Improved Cardiopulmonary Resuscitation Methods". NYU Langone News. Archived from the original on 2023-08-06. Retrieved 2023-08-06.
  31. ↑ Bostanciklioğlu M (January 2021). "Unexpected awakenings in severe dementia from case reports to laboratory". Alzheimer's & Dementia. 17 (1): 125–136. doi:10.1002/alz.12162. PMID   33064369. S2CID   222840626.
  32. ↑ "CTG Labs - NCBI". www.clinicaltrials.gov. Archived from the original on 2023-08-06. Retrieved 2023-08-06.
  33. ↑ "The Penn Program on Precision Medicine for the Brain". Penn Memory Center. Archived from the original on 2023-08-06. Retrieved 2023-08-06.
  34. 1 2 Gupta UC (January 2013). "Informed consent in clinical research: Revisiting few concepts and areas". Perspectives in Clinical Research. 4 (1): 26–32. doi: 10.4103/2229-3485.106373 . PMC   3601699 . PMID   23533976.
  35. ↑ Kim SY (May 2011). "The ethics of informed consent in Alzheimer disease research". Nature Reviews. Neurology. 7 (7): 410–414. doi:10.1038/nrneurol.2011.76. PMC   3475518 . PMID   21610690.
  36. ↑ Lingler JH, Jablonski RA, Bourbonniere M, Kolanowski A (July 2009). "Informed consent to research in long-term care settings". Research in Gerontological Nursing. 2 (3): 153–161. doi:10.3928/19404921-20090428-03. PMC   2889624 . PMID   20078005.
  37. 1 2 Ney DB, Peterson A, Karlawish J (December 2021). "The ethical implications of paradoxical lucidity in persons with dementia". Journal of the American Geriatrics Society. 69 (12): 3617–3622. doi:10.1111/jgs.17484. PMC   9924090 . PMID   34628640.
  38. ↑ Santos CS, Paiva BS, Lucchetti AL, Paiva CE, Fenwick P, Lucchetti G (August 2017). "End-of-life experiences and deathbed phenomena as reported by Brazilian healthcare professionals in different healthcare settings". Palliative & Supportive Care. 15 (4): 425–433. doi:10.1017/S1478951516000869. PMID   27890024. S2CID   206334016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.